Sign inJoin waitlistJoin the waitlist

Ardaman Shergill

Assistant Professor of Medicine · University of Chicago Medical Center

Credentials: · · · ·

History

University of Chicago Medical Center
Present

Hematology and Medical Oncology
University of Illinois College of Medicine
2009–2012
University of Illinois Hospital and Health Science
2009–2012
Wayne State University School of Medicine
2005–2009

Research

Preoperative Treatment of Locally Advanced Rectal Cancer
New England Journal of Medicine · 2023 · 399 citations
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet · 2023 · 299 citations
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
New England Journal of Medicine · 2025 · 127 citations

Kiran Turaga
31 papers
OE
Oliver Eng
24 papers · 2 as a fellow
Blase Polite
19 papers
EO
Eileen O'Reilly
16 papers
Jeffrey Meyerhardt
16 papers
Varun Bansal
16 papers · 16 as a resident
Ankit Dhiman
13 papers · 12 as a resident
MF
Michael Foote
9 papers
Cathy Eng
8 papers
DS
David Su
8 papers · 8 as a resident
EG
Elizabeth Godfrey
8 papers · 8 as a resident
Namrata Setia
8 papers

Clinical trials

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
Principal investigator · Recruiting · Phase 2
University of Chicago
2025–2026
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2024–2026
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Principal investigator · Suspended · Phase 1, Phase 2
University of Chicago
2022–2027
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030